Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tuberculosis Trial Design: FDA/Company Endpoint Talks Go Public At Cmte.

Executive Summary

The approval pathway for drugs to treat multi-drug resistant tuberculosis became somewhat clearer for sponsors as FDA's Anti-Infective Drugs Advisory Committee weighed in on clinical trial endpoints at a June 3 meeting

You may also be interested in...



J&J’s Sirturo Gets Panel Endorsement For Accelerated OK, Even As FDA Broaches Full Approval

FDA’s Anti-Infective Drugs Advisory Committee was fully satisfied with “sputum culture conversion” as a surrogate endpoint for accelerated approval, but turned back a last-minute question from FDA on traditional full approval for the tuberculosis drug bedaquiline.

FDA Encourages TB Drug Development But Wary Of Promoting Resistance

FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented

FDA Encourages TB Drug Development But Wary Of Promoting Resistance

FDA's approach to TB drug development demonstrates the traits Commissioner Margaret Hamburg wants in her agency - transparent, proactive, public health-oriented

Related Content

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel